With the data for the two chemotherapy regimens combined , the addition of bevacizumab to chemotherapy was associated with increased overall survival ( @ months vs. @ months ; hazard ratio for death , @ ; @ % confidence interval , @ to @ ; P = @ in a one-sided test ) and higher response rates ( @ % vs. @ % , P = @ ) .